20.500.12556/RUL-124557 DPP-4 inhibitors in the prevention/treatment of pulmonary fibrosis, heart and kidney injury caused by covid-19-a therapeutic approach of choice in type 2 diabetic patients? Since the outbreak of SARS-CoV-2 virus more than 12,500,000 cases have been reported worldwide. Patients suffering from diabetes and other comorbidities are particularly susceptible to severe forms of the COVID-19, which might result in chronic complications following recovery. Dipeptidyl peptidase-4 inhibitors exert beneficial effects in prevention/treatment of pulmonary fibrosis, heart, and kidney injury, and since they may be a long-term consequence caused by COVID-19, it is reasonable to expect that DPP-4 inhibitors might be beneficial in alleviating long-term consequences of COVID-19. With that in mind, we would like to voice our concerns over chronic implications following recovery from COVID-19, especially not only in diabetic but also in non-diabetic patients, and to indicate that some preventive measures could be undertaken by application of DPP-4 inhibitors. COVID-19 diabetes DPP-4 inhibitors fibrosis multi-organ injury COVID-19 poškodbe notranjih organov korona virus DPP-4 zaviralci pljučna fibroza true false true Angleški jezik Slovenski jezik Članek v reviji 2021-02-02 14:34:41 2021-02-02 14:34:45 2022-10-10 14:02:19 0000-00-00 00:00:00 2020 0 0 4 str. Vol. 11, art. 1185 2020 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.9+616.2 1663-9812 10.3389/fphar.2020.01185 25125123 29551833 RAZ_Smelcerovic_Andrija_2020.pdf RAZ_Smelcerovic_Andrija_2020.pdf 1 4E03EF535C418AF8D53F5B92F32A6D72 c4be06608f1c5a51d50c22d249caee26fd144b3093c3a9c223403d1862299560 95453e80-a1bb-11eb-a523-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=140086 https://www.frontiersin.org/articles/10.3389/fphar.2020.01185/full 1 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=140085 Fakulteta za farmacijo 0 0 0